SCHEMBL103308

SCHEMBL103308

[CH2]CC(C)CCCCCCCCCCCCCCCCCC

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ACE2 Q9BYF1 1/20 0.48
OPRM1 P35372 1/20 0.46
SPHK1 Q9NYA1 1/20 0.43
LMNA P02545 1/20 0.42
TSHR P16473 1/20 0.42
THRB P10828 1/20 0.42
DNM1 Q05193 2/20 0.42
ADH1B P00325 1/20 0.40
ADH1C P00326 1/20 0.40
ADH1A P07327 1/20 0.40
ADH4 P08319 1/20 0.40
ADH7 P40394 1/20 0.40
GPR84 Q9NQS5 3/20 0.38
FDPS P14324 3/20 0.38
FFAR1 O14842 1/20 0.38
CA1 P00915 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL102497 1.00 ACE2 (0.48) ACE2OPRM1SPHK1LMNATSHR
SCHEMBL201001 1.00 ACE2 (0.48) ACE2OPRM1SPHK1LMNATSHR
SCHEMBL199750 1.00 ACE2 (0.48) ACE2OPRM1SPHK1LMNATSHR
SCHEMBL102914 1.00 ACE2 (0.48) ACE2OPRM1SPHK1LMNATSHR
SCHEMBL101878 1.00 ACE2 (0.48) ACE2OPRM1SPHK1LMNATSHR
SCHEMBL7888892 1.00 ACE2 (0.48) ACE2OPRM1SPHK1LMNATSHR
SCHEMBL7939027 1.00 ACE2 (0.48) ACE2OPRM1SPHK1LMNATSHR
SCHEMBL101629 1.00 ACE2 (0.48) ACE2OPRM1SPHK1LMNATSHR
SCHEMBL103793 1.00 ACE2 (0.48) ACE2OPRM1SPHK1LMNATSHR
SCHEMBL199645 1.00 ACE2 (0.48) ACE2OPRM1SPHK1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024018761-A1 NEUTRAL LIPID AND LIPID NANOPARTICLE 国立大学法人北海道大学 2024-01-25 WO disclosed
WO-2024018762-A1 PH-SENSITIVE CATIONIC LIPID AND LIPID NANOPARTICLE 国立大学法人北海道大学 2024-01-25 WO disclosed
CN-103068786-B Cosmetic preparation COGNIS IP MANAGEMENT GMBH (DE) 2016-01-20 CN disclosed
US-8940943-B2 Cosmetic preparations COGNIS IP MANAGEMENT GMBH (DE) 2015-01-27 US disclosed
EP-2601166-A1 COSMETIC PREPARATIONS Cognis IP Management GmbH (DE) 2013-06-12 EP disclosed
US-20130131188-A1 Cosmetic Preparations COGNIS IP MANAGEMENT GMBH (DE) 2013-05-23 US disclosed
CN-103068786-A Cosmetic preparation COGNIS IP MAN GMBH 2013-04-24 CN disclosed
EP-2426101-A1 Cosmetic preparations Cognis IP Management GmbH (DE) 2012-03-07 EP disclosed
WO-2012016642-A1 COSMETIC PREPARATIONS COGNIS IP MANAGEMENT GMBH (DE) 2012-02-09 WO disclosed
CN-101076759-B Cleaning liquid for lithography and method for resist pattern formation TOKYO OHKA KOGYO CO LTD 2010-12-01 CN disclosed
CN-101076759-A Cleaning liquid for lithography and method for resist pattern formation TOKYO OHKA KOGYO CO LTD (JP) 2007-11-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131188-A1 Cosmetic Preparations CYP1B1, CBR1, ACOX3 ACE2 3825/4885OPRM1 745/4885SPHK1 1590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.